2014-12-02 21:02:30 UTC

Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis

Dec. 4, 2014

Reporting in Gastroenterology, Radha K. Dhiman and colleagues find that, over a six-month period, daily intake of the probiotic VSL#3 significantly improved liver function and reduced the risk of hospitalization for hepatic encephalopathy (HE).

Little is known about whether probiotics can affect outcomes of patients with cirrhosis and hepatic encephalopathy (HE). Radha K. Dhiman and colleagues assessed the efficacy of a probiotic preparation in preventing the recurrence of HE (primary outcome) and reducing the number of hospitalizations and severity of liver disease in patients with cirrhosis. Reporting in Gastroenterology, they find that, over a six-month period, daily intake of VSL#3 significantly reduced the risk of hospitalization for HE, as well as Child–Turcotte–Pugh and model for end-stage liver disease scores, in patients with cirrhosis.

Gastroenterology 2014: 147(6): 1327-1337.e3

More on Cirrhosis

Attend the AGA Postgraduate Course for Practical, Take Home Information

Feb. 12, 2018

Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.

Blog: Diagnosis, Pathogenesis and Treatment of Hepatorenal Syndrome in Patients With Cirrhosis

Jan. 30, 2018

New concepts and developments for diagnosis and assessment of renal function in patients with cirrhosis. Read more on the AGA Journals Blog.

Image Challenge: Cullen's Sign

Jan. 22, 2018

What caused a 56-year-old man with a previous history of cirrhosis to present with a large volume of ascites and periumbilical ecchymosis?